Literature DB >> 15655812

Selection of optimal antisense accessible sites of survivin and its application in treatment of gastric cancer.

Qiang-Song Tong1, Li-Duan Zheng, Fang-Min Chen, Fu-Qing Zeng, Liang Wang, Ji-Hua Dong, Gong-Cheng Lu.   

Abstract

AIM: To select the optimal antisense accessible sites of survivin, a highly expressed gene in tumor tissues, in order to explore a novel approach to improve biological therapy of gastric cancer.
METHODS: The 20 mer random oligonucleotide library was synthesized, hybridized with in vitro transcribed total survivin cRNA, then digested by RNase H. After primer extension and autoradiography, the antisense accessible sites (AAS) of survivin were selected. Then RNADraw software was used to analyze and choose the AAS with obvious stem-loop structures, according to which the complementary antisense oligonucleotides (AS-ODNs) were synthesized and transferred into survivin highly- expressing gastric cancer cell line MKN-45. Survivin expression was detected by RT-PCR and Western Blotting. Cellular growth activities were assayed by tetrazolium bromide (MTT) colorimetry. Cellular ultrastructure was observed by electronic microscopy, while apoptosis was detected by annexin V-FITC and propidium iodide staining flow cytometry.
RESULTS: Thirteen AAS of survivin were selected in vitro. Four AAS with stem-loop structures were chosen, locating at 207-226 bp, 187-206 bp, 126-145 bp and 44-63 bp of survivin cDNA respectively. When compared with non-tranfection controls, their corresponding AS-ODNs (AS-ODN(1), AS-ODN(2), AS-ODN(3) and AS-ODN(4)) could reduce Survivin mRNA levels in MKN-45 cells by 54.3+/-1.1% (t = 6.12, P<0.01), 86.1+/-1.0% (t = 5.27, P<0.01), 32.2+/-1.3% (t = 7.34, P<0.01) and 56.2+/-0.9% (t = 6.45, P<0.01) respectively, while survivin protein levels were decreased by 42.2+/-2.5% (t = 6.26, P<0.01), 75.4+/-3.1% (t = 7.11, P<0.01), 28.3+/-2.0% (t = 6.04, P<0.01) and 45.8+/-1.2% (t = 6.38, P<0.01) respectively. After transfection with 600 nmol/L AS-ODN1-AS-ODN(4) for 24 h, cell growth was inhibited by 28.12+/-1.54% (t = 7.62, P<0.01), 38.42+/-3.12% (t = 7.75, P<0.01), 21.46+/-2.63% (t = 5.94, P<0.01) and 32.12+/-1.77% (t = 6.17, P<0.01) respectively. Partial cancer cells presented the characteristic morphological changes of apoptosis, with apoptotic rates being 19.31+/-1.16% (t = 7.16, P<0.01), 29.24+/-1.94% (t = 8.15, P<0.01), 11.87+/-0.68% (t = 6.68, P<0.01) and 21.68+/-2.14% (t = 7.53, P<0.01) respectively.
CONCLUSION: The AAS of survivin could be effectively selected in vitro by random oligonucleotide library/RNase H cleavage method combined with computer software analysis, this has important reference values for further studying survivin-targeted therapy strategies for gastric cancer.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15655812      PMCID: PMC4250729          DOI: 10.3748/wjg.v11.i5.634

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  34 in total

Review 1.  Selecting optimal antisense reagents.

Authors:  M Sohail; E M Southern
Journal:  Adv Drug Deliv Rev       Date:  2000-10-31       Impact factor: 15.470

2.  Nucleic acid triggered catalytic drug and probe release: a new concept for the design of chemotherapeutic and diagnostic agents.

Authors:  Z Ma; J S Taylor
Journal:  Bioorg Med Chem       Date:  2001-09       Impact factor: 3.641

3.  Nucleic acid-triggered catalytic drug release.

Authors:  Z Ma; J S Taylor
Journal:  Proc Natl Acad Sci U S A       Date:  2000-10-10       Impact factor: 11.205

4.  Selection of antisense oligodeoxynucleotides against glutathione S-transferase Mu.

Authors:  Peter A C 't Hoen; Ruud Out; Jan N M Commandeur; Nico P E Vermeulen; F H D van Batenburg; Muthiah Manoharan; Theo J C van Berkel; Erik A L Biessen; Martin K Bijsterbosch
Journal:  RNA       Date:  2002-12       Impact factor: 4.942

5.  Potent antisense oligonucleotides to the human multidrug resistance-1 mRNA are rationally selected by mapping RNA-accessible sites with oligonucleotide libraries.

Authors:  S P Ho; D H Britton; B A Stone; D L Behrens; L M Leffet; F W Hobbs; J A Miller; G L Trainor
Journal:  Nucleic Acids Res       Date:  1996-05-15       Impact factor: 16.971

6.  RNA accessibility prediction: a theoretical approach is consistent with experimental studies in cell extracts.

Authors:  M Scherr; J J Rossi; G Sczakiel; V Patzel
Journal:  Nucleic Acids Res       Date:  2000-07-01       Impact factor: 16.971

7.  Theoretical design of antisense genes with statistically increased efficacy.

Authors:  M J Lehmann; V Patzel; G Sczakiel
Journal:  Nucleic Acids Res       Date:  2000-07-01       Impact factor: 16.971

Review 8.  Survivin in apoptosis control and cell cycle regulation in cancer.

Authors:  Dario C Altieri
Journal:  Prog Cell Cycle Res       Date:  2003

9.  Suppression of survivin expression inhibits in vivo tumorigenicity and angiogenesis in gastric cancer.

Authors:  Shui Ping Tu; Xiao Hua Jiang; Marie C M Lin; Jian Tao Cui; Yi Yang; Ching Tung Lum; Bing Zou; Yan Bo Zhu; Shi Hu Jiang; Wai Man Wong; Annie On-On Chan; Man Fung Yuen; Shiu Kum Lam; Hsiang Fu Kung; Benjamin Chun-Yu Wong
Journal:  Cancer Res       Date:  2003-11-15       Impact factor: 12.701

Review 10.  The future of antisense therapy: combination with anticancer treatments.

Authors:  Annamaria Biroccio; Carlo Leonetti; Gabriella Zupi
Journal:  Oncogene       Date:  2003-09-29       Impact factor: 9.867

View more
  2 in total

1.  Study on biological characters of SGC7901 gastric cancer cell-dendritic cell fusion vaccines.

Authors:  Kun Zhang; Peng-Fen Gao; Pei-Wu Yu; Yun Rao; Li-Xin Zhou
Journal:  World J Gastroenterol       Date:  2006-06-07       Impact factor: 5.742

2.  UBR5 regulates proliferation and radiosensitivity in human laryngeal carcinoma via the p38/MAPK signaling pathway.

Authors:  Kai Wang; Jun Tang; Xiaolei Liu; Yuejian Wang; Weixiong Chen; Rui Zheng
Journal:  Oncol Rep       Date:  2020-05-21       Impact factor: 3.906

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.